| 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| |
| 引用本文： | 陈雅蕊,王江涛,关泉林,姬薇,焦福智.抗体偶联药物在晚期非小细胞肺癌中的研究进展[J].肿瘤防治研究,2022,49(8):855-860. |
| |
| 作者姓名： | 陈雅蕊 王江涛 关泉林 姬薇 焦福智 |
| |
| 作者单位： | 1. 730000 兰州，兰州大学第一临床医学院；2. 730000 兰州，兰州大学第一医院肿瘤外科 |
| |
| 基金项目： | 甘肃省重点研究计划项目（2017YFC0908302） |
| |
| 摘 要： | 尽管靶向、免疫等治疗策略已成为晚期肺癌患者的一线标准疗法，但在多数情况下，获得性耐药仍不可避免。抗体偶联药物（ADC）的问世提供了一个全新的选择。ADC是一类由靶向抗肿瘤的单克隆抗体与细胞毒药物偶联形成的新型抗癌药物。与化疗药物相比，ADC具有耐受性好、靶点识别准确、对非癌细胞影响小等优点，已在多种恶性肿瘤治疗方面显示出良好的临床获益。本文就新兴的ADC在晚期非小细胞肺癌中的应用作一综述。
|
| 关 键 词： | 非小细胞肺癌 抗体偶联药物 靶向治疗 |
| 收稿时间： | 2021-12-16 |
Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer |
| |
| CHEN Yarui,WANG Jiangtao,GUAN Quanlin,JI Wei,JIAO Fuzhi.Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J].Cancer Research on Prevention and Treatment,2022,49(8):855-860. |
| |
| Authors: | CHEN Yarui WANG Jiangtao GUAN Quanlin JI Wei JIAO Fuzhi |
| |
| Institution: | 1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; 2. Department of Oncology Surgery, First Hospital of Lanzhou University, Lanzhou 730000, China |
| |
| Abstract: | Although targeted, immune and other therapeutic strategies have become the first-line standard therapy for patients with advanced lung cancer, acquired drug resistance is still inevitable in most cases. The advent of antibody-drug conjugates (ADC) provides a new choice. ADC is a new anticancer drug formed by the coupling of targeted anti-tumor monoclonal antibodies and cytotoxic drugs. Compared with chemotherapeutic drugs, ADC has the advantages of high tolerance, accurate target recognition and little effect on non-cancer cells, and has shown good clinical benefits in the treatment of a variety of malignant tumors. This article reviews the application of ADC in advanced non-small cell lung cancer. |
| |
| Keywords: | Non-small cell lung cancer Antibody-drug conjugates Targeted therapy |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
| 点击此处可从《肿瘤防治研究》下载免费的PDF全文 |
